Jiawang Xiao, Jianming Wang, Zhongchao Wang, Lili Meng, Ming Zhao, Qiguang Wang*
Congenital Heart Disease, Vol.19, No.3, pp. 293-303, 2024, DOI:10.32604/chd.2024.051427
- 26 July 2024
Abstract Background: Transcatheter closure (TCC) has emerged as the preferred treatment for selected congenital heart disease (CHD). While TCC offers benefits for patients with postoperative residual shunts, understanding its mid- and long-term efficacy and safety remains crucial. Objective: This study aims to assess the mid- and long-term safety and efficacy of TCC for patients with residual atrial or ventricular septal shunts following CHD correction. Methods: In this consecutive retrospective study, we enrolled 35 patients with residual shunt who underwent TCC or surgical repair of CHD between June 2011 to October 2022. TCC candidacy was determined based on… More >